Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
- PMID: 35501565
- DOI: 10.1038/s41409-022-01693-8
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
Erratum in
-
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.Bone Marrow Transplant. 2022 Dec;57(12):1854. doi: 10.1038/s41409-022-01834-z. Bone Marrow Transplant. 2022. PMID: 36207624 No abstract available.
Abstract
Limited data is available on factors impacting the outcomes of second hematopoietic cell transplantation (HCT2) in patients with secondary acute myeloid leukemia (sAML). This study aimed to assess HCT2 outcome for sAML comparing reduced-intensity (RIC) to myeloablative (MAC) conditioning. Two hundred and fifteen patients were included: RIC (n = 134), MAC (n = 81). The median follow-up was 41.1 (95% CI: 26.7-69.3) and 28.5 (95% CI: 23.9-75.4) months, respectively. At two years, the relapse incidence (RI) was 58.3% versus 51.1% in RIC and MAC, respectively. The 2-year leukemia free survival (LFS) was 26.6% versus 26%, and the graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) was 16.4% versus 12.1%, while OS was 31.4% and 39.7%, for RIC and MAC respectively. MVA showed a significantly lower RI [hazard ratio (HR) = 0.46 (95% CI, 0.26-0.8, p = 0.006)] and improved LFS [HR = 0.62 (95% CI, 0.39-0.98, p = 0.042)] with MAC versus RIC. The choice of conditioning regimen did not impact non-relapse mortality [HR = 1.14 (95% CI, 0.52-2.5, p = 0.74)], overall survival (OS) [HR = 0.72 (95% CI, 0.44-1.17, p = 0.18)] or GRFS [HR = 0.89 (95% CI, 0.59-1.36, p = 0.6)]. In conclusion, MAC was associated with a lower RI and superior LFS. These results support the use of MAC for eligible patients with sAML who are being considered for HCT2.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15. Am J Hematol. 2018. PMID: 29981272
-
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8. Transfus Apher Sci. 2013. PMID: 23981652
-
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.J Hematol Oncol. 2016 Mar 15;9:25. doi: 10.1186/s13045-016-0248-3. J Hematol Oncol. 2016. PMID: 26980295 Free PMC article.
-
Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Stem Cells Dev. 2014 Nov 1;23(21):2535-52. doi: 10.1089/scd.2014.0123. Epub 2014 Sep 17. Stem Cells Dev. 2014. PMID: 25072307 Free PMC article. Review.
-
Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.Transplant Cell Ther. 2021 Sep;27(9):782.e1-782.e7. doi: 10.1016/j.jtct.2021.06.011. Epub 2021 Jun 16. Transplant Cell Ther. 2021. PMID: 34146733
Cited by
-
Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT.Blood Adv. 2024 Aug 13;8(15):4223-4233. doi: 10.1182/bloodadvances.2024012798. Blood Adv. 2024. PMID: 38598754 Free PMC article.
-
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.Blood Cancer J. 2024 May 2;14(1):76. doi: 10.1038/s41408-024-01060-4. Blood Cancer J. 2024. PMID: 38697960 Free PMC article.
-
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.J Hematol Oncol. 2023 May 29;16(1):58. doi: 10.1186/s13045-023-01450-4. J Hematol Oncol. 2023. PMID: 37248463 Free PMC article.
-
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.Bone Marrow Transplant. 2024 Feb;59(2):217-223. doi: 10.1038/s41409-023-02139-5. Epub 2023 Nov 17. Bone Marrow Transplant. 2024. PMID: 37978322 Free PMC article.
References
-
- Granfeldt Ostgard LS, Medeiros BC, Sengelov H, Norgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National population-based cohort study. J Clin Oncol. 2015;33:3641–9. https://doi.org/10.1200/jco.2014.60.0890 . - DOI - PubMed
-
- Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208–14. https://doi.org/10.1002/ajh.23908 . - DOI - PubMed
-
- Della Porta MG. Prognosis of secondary acute myeloid leukemia. Leuk Res. 2013;37:857–8. https://doi.org/10.1016/j.leukres.2013.04.016 . - DOI - PubMed
-
- Park SH, Chi H-S, Cho Y-U, Jang S, Park C-J. Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 2013;48:185 https://doi.org/10.5045/br.2013.48.3.185 . - DOI - PubMed - PMC
-
- Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405–13. https://doi.org/10.1200/jco.2001.19.5.1405 . - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical